Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00179478 · ClinicalTrials.gov registry record · Phase 4

Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis

A Phase 4 study of Multiple Sclerosis and Optic Neuritis, sponsored by Beth Israel Deaconess Medical Center.

Completed
Registry status
Phase 4
Development phase
155
Enrollment target
20
Study locations

NCT00179478: Completed Phase 4 study of Multiple Sclerosis and Optic Neuritis, sponsored by Beth Israel Deaconess Medical Center.

NCT00179478 is a Phase 4 study of Multiple Sclerosis and Optic Neuritis that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 155 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00179478, a Phase 4 study of Multiple Sclerosis and Optic Neuritis, has completed, sponsored by Beth Israel Deaconess Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
155 participants
Enrollment target
20
Study locations

Study Summary

The current study is a continuation of the 5 year extension study of the phase III CHAMPS study (see reference). This study was designed to determine if immediate initiation of therapy with Interferon Beta-1a (AVONEX) after a first attack of multiple sclerosis (MS) continues to delay the development of further attacks (CDMS) and the development of neurological disability over a 10 year period of observation. The initial 5 year extension study, called CHAMPIONS5, reported that immediate initiation of interferon Beta-1a (AVONEX) after a first attack of MS continued to delay the development of CDMS and lowered relapse rates compared to delayed initiation of disease modifying treatment (usually with AVONEX) either at the time of a second attack or at the end of the phase III study (24 months). The study was extended to 10 years to determine if these effects are sustained and result in less long term permanent disability.

Primary Outcome

Percent cumulative probability of developing CDMS over 10 years . CDMS was defined as the development of new visual or neurological symptoms discrete from the patients initial event with objective findings on examination.

Conditions Studied

Multiple Sclerosis Optic Neuritis Transverse Myelitis Acute Brainstem/Cerebellar Syndrome

Interventions

  • DRUG interferon beta 1a 30 ug IM once weekly

Study Locations (20)

Pennsylvania

  • The Neurology Group - Norristown
  • Univeristy of Pennsylvania Medical Center - Philadelphia
  • Allegheny Neurological Associates - Pittsburgh

New York

  • Jacobs Neurological Institute - Buffalo
  • University of Rochester - Rochester

Ohio

  • Cleveland Clinic Foundation - Cleveland
  • The Ohio State University - Columbus

Virginia

  • Virginia Commonwealth University/Medical College of Virginia - Richmond
  • Neurological Associates, Inc. - Richmond

Connecticut

  • MS Treatment Center at Griffin Hospital - Derby

Florida

  • Jaeb Center for Health Research - Tampa

Georgia

  • MS Center of Atlanta - Atlanta

Illinois

  • Beta Research, Inc - Elk Grove

Trial Details

FieldValue
Enrollment Target 155 participants
Start Date 2001-02
Est. Completion 2009-03
Phase Phase 4
Beth Israel Deaconess Medical Center

488 total trials

What the finished NCT00179478 record still lists

NCT00179478 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (74% lower).

The record links to 4 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which interferon beta 1a 30 ug IM once weekly is the first listed.

NCT00179478 names 20 study sites across 15 states, led by Pennsylvania, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT00179478 about?

NCT00179478 is a clinical study titled "Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis". The current study is a continuation of the 5 year extension study of the phase III CHAMPS study (see reference). This study was designed to determine if immediate initiation of therapy with Interferon Beta-1a (AVONEX) after a first attack of multiple sclerosis (MS) continues to delay the development...

What is the current status of trial NCT00179478?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 155 participants. The study started on 2001-02. Estimated completion is 2009-03.

What conditions does trial NCT00179478 study?

This clinical trial studies the following conditions: Multiple Sclerosis, Optic Neuritis, Transverse Myelitis, Acute Brainstem/Cerebellar Syndrome.

What interventions are being tested in trial NCT00179478?

The interventions under investigation include: interferon beta 1a 30 ug IM once weekly (DRUG).

Who is sponsoring clinical trial NCT00179478?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00179478 being conducted?

This trial has 20 study locations across Connecticut, Florida, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00179478's enrollment target sits among peer trials

155 92nd of 315 higher than 224 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03223610 · 155 participants · Phase 1

    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

  • NCT05072483 · 155 participants

    Natural History Study of CADASIL

  • NCT05086497 · 155 participants · NA

    WBSI Guided Personalized Delivery of TTFields

  • NCT05412069 · 155 participants · NA

    Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00179478, the US trial registry maintained by the National Library of Medicine. NCT00179478 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.